ResMed (RMD) 10-K Summaries & Annual Filing History
Review ResMed Inc. (RMD) 10-K filings from 2023 through the latest annual report, including business, financial performance, risks, and liquidity.
Key takeaway
Year ended Jun 30, 2025 · FY2025 10-K
ResMed Inc. filed its annual report for the most recent fiscal year. The filing describes the company's business, financial results, risk factors, and liquidity position.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$5.1B
Revenue reported for the fiscal year.
Operating income
$1.7B
Income from operations reported for the year.
Net income
$1.4B
Net income reported for the year.
Operating cash flow
$1.8B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2022 | $3.6B | +11.9% |
| Jun 30, 2023 | $4.2B | +18.0% |
| Jun 30, 2024 | $4.7B | +10.9% |
| Jun 30, 2025 | $5.1B | +9.8% |
Business overview
ResMed develops, manufactures, and distributes medical devices and cloud-based software solutions for the treatment of respiratory disorders. The company's products are used primarily in the sleep apnea and chronic obstructive pulmonary disease markets. Its operations include research and development, selling and marketing, and strategic acquisitions.
Financial performance
Revenue increased compared to the prior year, continuing a multi-year upward trend. Operating income and net income both grew, and cash generated from operations remained strong. The company's financial direction reflects sustained growth in its core markets.
Material risks
The filing identifies risks including supply chain disruptions that could affect operating results and working capital. Future capital requirements depend on factors such as revenue growth rate, third-party reimbursement, and spending on research and development. The company may need external financing for inorganic growth strategies.
Liquidity and capital
Principal liquidity sources are existing cash, cash equivalents, operating cash flow, and a revolving credit facility. Cash is used for research and development, selling and marketing, capital expenditures, acquisitions, share repurchases, dividends, and debt repayment.
What to watch
Monitor the company's ability to maintain revenue growth and operating cash flow amid potential supply chain disruptions.